

References

I-113

1. Yeo W, Luk M, Soong I, et al. Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. *Hong Kong Med J*. 2018;24:1-7.
2. Hurvitz S, Martin M, Symmans W F, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2018;19(1):12-13.
3. Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GATSBY): an international randomized, open-label, adaptive, phase 2/3 study. *The Lancet*. 2017;18(5):640-653.
4. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Eng J Med*. 2019;380(7):617-628.
5. National Comprehensive Cancer Network (NCCN). Ado-trastuzumab emtansine. NCCN Drugs and Biologics Compendium®. 2023.
6. Clinical Pharmacology™ 2023. Tampa FL: Gold Standard, Inc. Ado-trastuzumab emtansine.
7. Micromedex DrugDex Compendium®. 2023. Ado-trastuzumab emtansine.
8. Kadcyla (ado-trastuzumab emtansine) for injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 2/2022
9. Lu D, Li C, Riggs M, et al. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. *Cancer Chemother Pharmacol*. 2019;84(1):175185.
10. Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. *J Hematol Oncol*. 2020;13(1):1-23.
11. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. *J Clin Oncol*. 2018;36(24):2532-2537.
12. [Ado-trastuzumab emtansine] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 6, 2016.
13. Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain

metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. *Ann Oncol.* 2020; 31(10):1350-1358.

14. Cortés J, Diéras V, Lorenzen S, et al. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial. *JAMA Oncol.* 2020;6(8):1203-1209.
15. Masuda N, Ohtani S, Takano T, et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. *Breast Cancer Res Treat.* 2020;180(1):135-146